Abstract 270P
Background
The companion diagnostic for olaparib against prostate cancer, which aims to detect BRCA1 or BRCA2 gene (BRCA1/2) variants, was investigated in December 2020 in Japan. There have been no reports on germline BRCA1/2 variants in actual clinical practice. Here, we evaluate germline BRCA1/2 variants and their relationship to the clinical characteristics and outcomes in prostate cancer.
Methods
Between June 2021 and June 2023, 92 patients with prostate cancer were examined using germline BRCA1/2 testing. Further, the associations between pathogenic variants and clinical outcomes were assessed.
Results
Of the 92 patients referred from the Iwate prefecture in Japan for genetic testing, six patients (6.5%) carried germline pathogenic variants; BRCA2 was the most frequent (n=5, 5.4%), followed by BRCA1 (n=1, 1.1%). Among the six variants in BRCA2, p.Ala338Valfs*11 was identified for the first time. Patients with the BRCA1/2 variant exhibited poor outcomes for overall survival from castration-resistant prostate cancer (CRPC), first-line androgen receptor-axis-targeted therapy (ARAT) for CRPC, and taxane chemotherapy (hazard ratio [HR] 4.77, 95% CI: 1.00 to 22.6, P=0.049; HR=5.27, 95% CI: 1.77 to 15.7, P=0.0028; and HR=7.47, 95% CI: 1.49 to 37.4, P=0.014, respectively).
Conclusions
In this study, patients with prostate cancer possessing germline variants of BRCA1/2 genes exhibited poor clinical response to ARAT for CRPC and taxane chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
310P - A study on the prediction of recurrence site of endometrial cancer using various machine learning techniques
Presenter: Wonkyo Shin
Session: Poster Display
Resources:
Abstract
311P - Circulating cytokines in the differential diagnosis of endometrial cancer
Presenter: Tatyana Abakumova
Session: Poster Display
Resources:
Abstract
312P - Molecular and genetic features of squamous cell carcinoma of vulvar cancer depending on HPV status
Presenter: Visola Navruzova
Session: Poster Display
Resources:
Abstract
313P - Efficacy and safety of oral metronomic chemotherapy in recurrent refractory advanced gynaecological cancer: Experience from regional cancer center of eastern India
Presenter: Ranti Ghosh
Session: Poster Display
Resources:
Abstract
314P - Perioperative outcomes in advanced epithelial ovarian cancer treated with neoadjuvant bevacizumab and chemotherapy: Real-world experience from an Indian cancer centre
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
315P - Real-world experience of niraparib as maintenance therapy in newly diagnosed advanced ovarian cancer: A single-center retrospective study
Presenter: Wenxin Liu
Session: Poster Display
Resources:
Abstract
316P - First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study
Presenter: Jing Li
Session: Poster Display
Resources:
Abstract
317P - Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy
Presenter: wisam Assaf
Session: Poster Display
Resources:
Abstract
319P - Survival prediction for ovarian cancer patients from Taiwan cancer registry data
Presenter: Tzu-Pin Lu
Session: Poster Display
Resources:
Abstract
320P - Treatment patterns and outcomes in Indian patients with advanced ovarian cancer: A single center experience
Presenter: Pushpendra Hirapara
Session: Poster Display
Resources:
Abstract